EPHB2 Antibody - #AF5246

Fig. 4 EphrinB2 overexpression promoted osteogenic differentiation of hDPSCs partially via enhancement of ephrinB2-mediated reverse signaling. a Overexpression of ephrinB2 elevated p-ephrinB2 but did not affect p-EphB4 and RhoA activity in hDPSCs during osteogenic differentiation. b Western blot analysis confirmed that ephrinB2 reverse signaling was activated by 1 μg/ml EphB4-Fc. c Alizarin Red S staining of hDPSCs treated with EphB4-Fc at different concentrations (0, 2, and 4 μg/ml) in osteogenic medium for 14 days. Scale bar = 200 μm. d Transcription of RUNX2, BMP2, and OCN in EphB4-Fc-treated hDPSCs on day 7 of osteogenic induction. Data are shown as mean ± SD. Assays were repeated three times. *p < 0.05 and **p < 0.01

Figure S1.| Expression patterns of EphB1, EphB2, and EphB4 in ephrinB2-overexpressing hDPSCs. (A) EphB4 mRNA expression level was lower in ephrinB2-overexpressing hDPSCs on days 0 and 7 of osteogenic induction. (B) EphB4 protein expression level was lower in ephrinB2-overexpressing hDPSCs on days 0 and 7 of osteogenic induction. (C) Overexpression of ephrinB2 did not affect EphB1 and EphB2 protein expression levels. Data are shown as mean ± SD. Assays were repeated three times. *p < 0.05 and **p < 0.01 (TIF 10113 kb)

Fig. 5 tDCS upregulate expression level of EPHB2, ephrinb1, MAP-2, NMDAR in the hippocampal of CI mice. a The values of mRNA expression. b Results are immunoblots from single representative experiment. c The values of protein expression. The data are expressed as the mean±SD (n=4). *P<0.05, **P<0.01 compared with Sham group, # P<0.05, ##P<0.01 compared with Model group

Fig 11. Expression of the four prognostic MRGs in eight pairs of tissues was detected by western blotting (T, COAD tissue;C, adjacent tissue). (A) EPHB2, (B) PPARGC1A, (C) SLC6A1, (D) PPP1R17.